Cure My Disease

Don't miss your cure!

 Log in / Sign up

New kidney drug enters first human tests

NCT ID NCT07235059

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 16, 2026 · Updated 3 times

Summary

This early-stage trial tests a new drug called OJR520 in healthy volunteers and people with chronic kidney disease. The main goal is to check if the drug is safe and how the body processes it. About 112 participants will receive either OJR520 or a placebo. This is the first time the drug is being tested in humans.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
OJR520
What this could lead to
If this drug is safe and shows promise, it could point toward a new treatment option for chronic kidney disease.
What could go wrong
This is a very early, first-in-human trial with only 112 participants. The drug may not work or could have side effects. It will take years to know if it helps patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome diabetic kidney disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC KIDNEY DISEASE

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-••••

Locations

  • Novartis Investigative Site

    RECRUITING

    Berlin, 10117, Germany

  • Quotient Sciences Sea View

    RECRUITING

    Miami, Florida, 33126, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.